Bright Minds Biosciences (Bright Minds Biosciences) Equity-to-Asset : 0.88 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Bright Minds Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $4.50 Mil. Bright Minds Biosciences's Total Assets for the quarter that ended in Dec. 2023 was $5.13 Mil.

The historical rank and industry rank for Bright Minds Biosciences's Equity-to-Asset or its related term are showing as below:

DRUG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.83 Med: 0.95 Max: 0.99
Current: 0.88

During the past 4 years, the highest Equity to Asset Ratio of Bright Minds Biosciences was 0.99. The lowest was 0.83. And the median was 0.95.

DRUG's Equity-to-Asset is ranked better than
82.47% of 1563 companies
in the Biotechnology industry
Industry Median: 0.66 vs DRUG: 0.88

Bright Minds Biosciences Equity-to-Asset Historical Data

The historical data trend for Bright Minds Biosciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Equity-to-Asset Chart

Bright Minds Biosciences Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Equity-to-Asset

0.83

0.97

0.87

0.96

Bright Minds Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial												0.95	0.90	0.91	0.96	0.88

Competitive Comparison of Bright Minds Biosciences's Equity-to-Asset

For the Biotechnology subindustry, Bright Minds Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bright Minds Biosciences's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's Equity-to-Asset falls into.

Bright Minds Biosciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Bright Minds Biosciences's Equity to Asset Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Equity to Asset (A: Sep. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	4.876	/	5.084
	=

Bright Minds Biosciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	4.497	/	5.133
	=

Bright Minds Biosciences (NAS:DRUG) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Bright Minds Biosciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bright Minds Biosciences (Bright Minds Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (NAS:DRUG) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

DRUG:Canada

Address

19 Vestry Street, New York, NY, USA, 10013

Website

https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.